Columbia University
New York, 10032, United States
Location status: Recruiting
NCT Number: NCT05189314
The purpose of this observational research is to evaluate and compare clinical outcomes after treatment for symptomatic benign multinodular goiter (MNG) patients. This is a data collection study in which we ask participants to give access to information generated before and after treatment of their condition.
Interested in participating?
Request Info18 year and older
All sexes
Observational
New York, 10032, United States
Location status: Recruiting
Benign multinodular goiter (MNG) refers to an enlarged thyroid gland with nodules within it, frequently owing to iodine deficiency. It is the most common endocrine disorder worldwide.
Significant growths of nodules can cause symptomatic compressive symptoms such as dysphagia, dyspnea, or vascular compression of the neck vessels. On occasion, these nodules can develop autonomy and secrete excess thyroid hormone (toxic multinodular goiter). Surgical resection has been the preferred treatment option for symptomatic multinodular goiters and addresses both compressive symptoms as well as hyperthyroidism, but is associated with small, but not negligible risk of nerve injury, hypoparathyroidism, and may confer a risk of hypothyroidism and dependence on thyroid hormone supplementation.
Thermoablative methods that induce local thermodestruction leading to nodule shrinkage and improvement in local symptoms and hyperthyroidism have recently emerged as a possible alternative treatment approach for MNG. Monopolar radiofrequency ablation (RFA) is presently the best documented thermoablative technique. Although RFA of thyroid nodules specifically, is still considered investigational in the United States, RFA of thyroid nodules has been used by several centers globally (mainly in South Korea, Italy, China, and Austria) since 2006 with excellent clinical outcomes. In addition, RFA of other solid tumors is a commonly performed procedure in the United states and all RFA devices, including the device that we will use for the clinical care of these patients, are cleared by the FDA (New devices/technology to the market are approved, but devices that have a predicate device/technology that are already on the market only need to be cleared). In response to its increasing popularity, the Korean Society of Thyroid Radiology commissioned a Task Force to develop recommendations for the optimal use of radiofrequency ablation for thyroid tumors in 2012, and these recommendations were recently revised in 2017 and the American Association of Clinical Endocrinologists recently recommended that ultrasound guided thermal ablation treatments be considered for solid or mixed symptomatic benign thyroid nodules.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Surgical Resection of thyroid nodules
Radiofrequency Ablation of thyroid nodules
Time frame: 6 months and 12 months
Percent Volume Change of Nodules: ((Volume (baseline) - Volume (*m*))/Volume(baseline))*100
Time frame: 6 months and 12 months
Change in serum TSH
Time frame: 12 months
The Thypro 39 is a survey assessing quality of life in patients with thyroid disease. Scores range from 0-100 with a higher score indicating a worse outcome.
Contact information is provided by the study sponsor or research team.
Jennifer H Kuo, MD MS
CONTACT
Vilma Rosario
CONTACT
Columbia University
Other
Clinical Outcomes and Quality of Life Measures After Surgical Resection and Radiofrequency Ablation of Benign Thyroid Nodules
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07226804
Endocrine Gland Neoplasms, Endocrine System Diseases
Houston, Texas, United States
View Trial DetailsNCT06340945
Endocrine Gland Neoplasms, Endocrine System Diseases
Beijing, China
View Trial DetailsNCT07360587
Endocrine Gland Neoplasms, Endocrine System Diseases
Sherbrooke, Quebec, Canada
View Trial DetailsNCT07299474
Chronic Rhinosinusitis (CRS), Endocrine Gland Neoplasms
Los Angeles, California, United States
View Trial Details